Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity.
about
Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cellsNano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degenerationBioadhesive hyaluronan-chitosan nanoparticles can transport genes across the ocular mucosa and transfect ocular tissue.Nanoparticles for local drug delivery to the oral mucosa: proof of principle studies.Recent advances of chitosan nanoparticles as drug carriersDevelopment of drug-loaded chitosan-vanillin nanoparticles and its cytotoxicity against HT-29 cells.Natural extracts into chitosan nanocarriers for rosmarinic acid drug delivery.Brimonidine tartrate-eudragit long-acting nanoparticles: formulation, optimization, in vitro and in vivo evaluation.Low molecular weight chitosan nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery.Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium: Improved permeation, retention, and penetration.The potential of chitosan for the oral administration of peptides.Microfabricated photocrosslinkable polyelectrolyte-complex of chitosan and methacrylated gellan gumThe performance of nanocarriers for transmucosal drug delivery.Ocular drug delivery: nanomedicine applications.Nanoparticles in modern medicine: state of the art and future challenges.Development, characterization, and in vivo assessment of mucoadhesive nanoparticles containing fluconazole for the local treatment of oral candidiasis.Encapsulation of Cardamom Essential Oil in Chitosan Nano-composites: In-vitro Efficacy on Antibiotic-Resistant Bacterial Pathogens and Cytotoxicity Studies.Chitosan nanoparticles for drug delivery to the eye.Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone.Toxicity of nanomaterials to the eye.NANOTECHNOLOGY IN THE TREATMENT AND DETECTION OF INTRAOCULAR CANCERS.Ocular drug delivery - a look towards nanobioadhesives.Topical drug delivery using chitosan nano- and microparticles.Recent advances in ocular drug delivery.Drug delivery systems: Advanced technologies potentially applicable in personalized treatments.Impacts of nanomedicines in ocular pharmacotherapyNanocarriers for ocular delivery for possible benefits in the treatment of anterior uveitis: focus on current paradigms and future directions.Effects of nanoparticles in species of aquaculture interest.Polymeric nanobiocomposites for biomedical applications.Potential chitosan-coated alginate nanoparticles for ocular delivery of daptomycin.Drug delivery to the eye: what benefits do nanocarriers offer?Nanoparticles for drug delivery to the anterior segment of the eye.Methotrexate-loaded chitosan- and glycol chitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors.Low molecular weight chitosan-coated liposomes for ocular drug delivery: in vitro and in vivo studies.Imidazole-grafted chitosan-mediated gene delivery: in vitro study on transfection, intracellular trafficking and degradation.Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.Formulation, characterization and testing of tetracaine hydrochloride-loaded albumin-chitosan microparticles for ocular drug delivery.Formulation and corneal permeation of ketorolac tromethamine-loaded chitosan nanoparticles.Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy.Nanoparticles laden in situ gel for sustained ocular drug delivery
P2860
Q28475072-5237B353-113E-4C18-BD31-A53B4739D600Q30565636-8F2B49D1-B085-4DAE-BD88-B22FB0E69296Q33321483-120D55D8-7972-4203-A0D7-B2D4698CFF44Q33906978-31169D12-FF04-4727-8EF4-854D9383E250Q34956317-B3C6B4D9-BBB2-4D83-A60D-0B6729158F04Q35142515-1FEE7996-57A7-4644-9D05-EFF4B41C980CQ35502502-F82B5A1D-0420-432D-B592-DC11BB3D015BQ35577210-DE1E9DC0-D0B2-4164-AC6C-D07A942964A6Q35846845-BDE58CC5-BE6D-4739-BFAE-00AAAA387476Q35981514-89204B53-C95A-4141-9E63-907A9247038DQ36316822-D1620AEE-7DE3-49D8-8765-FEF334D82FDDQ36501901-9724F2A1-4F6C-498A-9D0E-21EF76FB7ADCQ36527739-4E215B29-321F-4316-B426-2CFEBE122EE6Q36918036-12306926-BE2D-4DC5-8E0C-530092F8126CQ36920457-371E3C92-8D91-4C01-B038-90E854D727ADQ37016879-41FF1AF8-DF93-4AAC-8C59-EC9CD59565CEQ37306859-9EA89D62-1FEA-4D12-A32B-4F7B69C91DFDQ37416144-72B19359-C01B-4FC8-ACEA-1F66F48F5D07Q37652843-0E91CE20-792A-4268-88D9-4F4E7CC92596Q37676123-D583356F-A21E-46C6-A815-EC8DB375922CQ37776418-317D61EF-3BEA-4900-B3F8-06F2CDD91252Q37822756-DE201D8C-8A05-4D14-878A-5D6113492F61Q38024402-4FDCE2C6-BF53-4644-811A-46574D2254A9Q38059884-65F0BEB2-5635-41F1-99DE-35AAD19A5D61Q38063945-99E78288-BE9D-4981-9436-AFFE8D28CF0FQ38107200-E81F05B4-18EA-4B53-A18D-7AFB73F1971BQ38227621-B2BA16C5-2C61-47F7-8084-7C0CF5E014F9Q38672997-14D3B6F7-79CD-4962-A62A-66691ED0C46EQ38748582-9B332C59-B44C-4ADE-9577-3FE1CF292977Q38901841-E1E9ADF0-6A20-4FB2-875C-DEAAC1FB7094Q39130097-FFADF32B-B55B-4183-ABAF-1E5E5D866140Q39230212-693D53B1-C057-499B-9966-4038CC2A9D7AQ39424092-CC40137F-F096-4DFA-9E68-20AC991DFFBAQ39445881-701026A2-1FAF-496D-9710-78ED9F65E210Q39455958-2B99E37E-164A-4588-BAA3-05A78B62A720Q39557119-51009631-8C27-4960-84E3-8CD22D026204Q39754854-5E7DD472-07F5-4FA3-96E2-C878C376205AQ40500729-B11661AD-EBAF-43CA-A7B3-9DBB5E77CA4CQ40549525-ABBC93AF-AC07-430F-B6F0-ED7E07D50154Q41448124-D29C4C6A-FDC8-41C3-A82F-1067566CCD4D
P2860
Chitosan nanoparticles as new ocular drug delivery systems: in vitro stability, in vivo fate, and cellular toxicity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Chitosan nanoparticles as new ...... o fate, and cellular toxicity.
@en
type
label
Chitosan nanoparticles as new ...... o fate, and cellular toxicity.
@en
prefLabel
Chitosan nanoparticles as new ...... o fate, and cellular toxicity.
@en
P2093
P1476
Chitosan nanoparticles as new ...... o fate, and cellular toxicity.
@en
P2093
Alejandro Sánchez
Angela M de Campos
Edison L S Carvalho
Maria José Alonso
Yolanda Diebold
P304
P356
10.1023/B:PHAM.0000026432.75781.CB
P577
2004-05-01T00:00:00Z